Baymatob, an Australian medical device company, has received funding from the New South Wales Medical Devices Fund to advance Oli, an AI-powered maternal-fetal health platform designed to provide early warning for serious complications in pregnancy and labor including postpartum hemorrhage, stillbirth, and uterine rupture. The funding was part of a A$7.4 million round awarded to four medical device companies.
Postpartum hemorrhage is one of the leading causes of maternal mortality in Australia and the leading cause of preventable maternal death worldwide. In NSW, around one in five women experience a postpartum hemorrhage, and globally a mother dies from PPH every seven minutes – yet up to 93% of these deaths are preventable with earlier recognition and faster clinical response.
“Our Oli innovation aims to make pregnancy and childbirth safer for all mothers and babies by predicting complications before they occur, so that they can be prevented,” said Baymatob CEO Tara Croft. “This is exactly where Oli can make a difference, supporting clinicians to identify risks sooner and intervene earlier to save lives.”
Trials are underway at Royal North Shore Hospital and The Royal Hospital for Women in Australia, as well as in the United States. The funding will accelerate clinical trials and deep-tech development.
